What is Optimi?
Optimi Health operates as a sophisticated player in the health and wellness industry, specializing in the cultivation, processing, and distribution of high-quality functional mushroom products. The company distinguishes itself through a vertically integrated approach, utilizing two state-of-the-art facilities in Princeton, British Columbia, spanning 20,000 square feet. Beyond commercial production, Optimi is deeply embedded in scientific research through its subsidiary, Optimi Labs Inc. By securing research exemptions under Health Canada Food and Drug Regulations, the firm is actively investigating the therapeutic potential of Psilocybin and Psilocin. This dual-track strategy—combining commercial wellness products with rigorous pharmaceutical-grade research—positions Optimi as a high-authority entity in the evolving fungi-based therapeutics market.
How much funding has Optimi raised?
Optimi has raised a total of $3.3M across 2 funding rounds:
Debt
$2.2M
Share Placement
$1.1M
Debt (2023): $2.2M, investors not publicly disclosed
Share Placement (2024): $1.1M, investors not publicly disclosed
Key Investors in Optimi
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Optimi?
Looking ahead, the infusion of capital will likely be directed toward the finalization of its production facilities and the pursuit of a dealer's license under Canada's Narcotic Control Regulations. As the company transitions from infrastructure development to full-scale commercialization, the focus will shift toward market penetration and the expansion of its research pipeline. Strategic priorities include the optimization of laboratory analysis for Psilocybin formulations and the scaling of distribution networks. Investors will be monitoring the company's ability to translate its regulatory milestones into tangible revenue streams, particularly as the global interest in psychedelic-assisted therapy continues to gain institutional momentum. The company's commitment to expert cultivation and adherence to stringent legal frameworks remains the cornerstone of its long-term growth strategy.
See full Optimi company page
